

## DAFTAR PUSTAKA

1. Verhelst X, Geerts A, Vlierberghe H Van. Cirrhosis: Reviewing the Literature and Future Perspectives. *Cit EMJ*. 2016;1(3):111–7.
2. NIDDK (2018). Definition and facts for cirrhosis. National Institute of Diabetes and Digestive and Kidney Diseases. <https://www.niddk.nih.gov/health-information/liver-disease/cirrhosis/definition-facts> - Diakses Juni 2019
3. Wong MCS, Huang J. The growing burden of liver cirrhosis: implications for preventive measures. *Hepato Int*. 2018;12(3):201–3.
4. PPHI (2013). Sirosis hati. Perhimpunan Peneliti Hati Indonesia. <http://pphionline.org/alpha/?p=570> - Diakses Juni 2019
5. Elfatma Y, Rachmawati N. Artikel Penelitian Gambaran Derajat Varises Esofagus Berdasarkan Beratnya Sirosis Hepatis. 2017;6(2):457–62.
6. Azmi I. Hubungan berat ringannya sirosis hepatitis dengan derajat varises esofagus (skripsi). Universitas Andalas; 2017.
7. Nurdjanah S. Sirosis Hati. In: Setiati S, Alwi I, Sudoyo AW, Simadibrata K M, Setiyohadi B, Syam FA, editors. *Buku Ajar Ilmu Penyakit Dalam*. 6th ed. Jakarta: InternaPublishing; 2014. p. 1980-85.
8. D'Amico G, Morabito A, D'Amico M, Pasta L, Malizia G, Rebora P, et al. Clinical states of cirrhosis and competing risks. *J Hepatol*. 2018;68(3):563–76.
9. D'Amico G, Pasta L, Morabito A, D'Amico M, Caltagirone M, Malizia G, et al. Competing risks and prognostic stages of cirrhosis: A 25-year inception cohort study of 494 patients. *Aliment Pharmacol Ther*. 2014;39(10):1180–93.
10. Kim HJ, Lee HW. Important predictor of mortality in patients with end-stage liver disease. *Clin Mol Hepatol*. 2013;19(2):105.
11. Devrajani BR, Asif M, Talpur A, Atta-ur-rahman A. Coagulopathies in Patients with Liver Cirrhosis. *World Appl Sci J*. 2012;17(1):1–4.
12. Carvalho JR, Machado MV. New insights about albumin and liver disease. *Ann Hepatol*. 2018;17(4):547–60.
13. Rahmafritria, Mutmainnah, Samad A ibrahim. Tolak Ukur Fungsi Hati Berdasarkan Derajat Fibrosis Penyakit Hati Kronis. *Indones J Clin Pathol Med Lab*. 2014;21(1):57–60.
14. Wira NT. Hubungan Nilai Prothrombin Time dan Albumin Dengan Staging Pasien Sirosis Hepatis di RSUP. Dr. Wahidin Sudirohusodo Makassar Periode Januari - Desember 2016 (skripsi). Universitas Hasanuddin; 2017.
15. Labidi A, Baccouche H, Fekih M, Mahjoub S, BenMustapha N, Serghini M, et al. The relationship between coagulation disorders and the risk of bleeding in cirrhotic patients. *Ann Hepatol*. 2019;18(4):627–32.
16. Sakata M, Kawaguchi T, Taniguchi E, Nakayama A, Ishizaki S, Sonaka I, et al. Oxidized albumin is associated with water retention and severity of disease in patients with chronic liver diseases. *Eur e-journal Clin Nutr Metab*. 2010;5(6):247–53.

17. Zipprich A, Garcia-Tsao G, Rogowski S, Fleig WE, Seufferlein T, Dollinger MM. Prognostic indicators of survival in patients with compensated and decompensated cirrhosis. *Natl Institutes Heal.* 2012;32(9):1407–14
18. Kapoor VK, Gest T. Liver Anatomy. *Medscape Ref.* 2012;6–11.
19. Sibulesky L. Normal liver anatomy. *Clin Liver Dis.* 2013;2(1):1–4.
20. Sherwood L. Fisiologi Manusia dari Sel ke Sistem. 6th ed. Yesdelita N, editor. Jakarta: EGC; 2011. 669–670 p.
21. Ozougwu JC. Physiology of the liver. *Int J Res Pharm Biosci.* 2017;4(8):13–24.
22. John E H. Guyton dan Hall Buku Ajar Fisiologi Kedokteran. 12th ed. Ibrahim Ilyas EI, Widjajakusumah MD, Tanzil A, Santoso DIS, editors. Singapore: Elsevier; 2014. 910–911 p.
23. Garcia Tsao G. Cirrhosis and Its Sequelae. In: Goldman L, Schafer AI, editors. *Goldman-Cecil Medicine.* 24th ed. Philadelphia: Elsevier; 2012. p. 999–1007.
24. Mokdad AA, Lopez AD, Shahraz S, Lozano R, Mokdad AH, Stanaway J, et al. Liver cirrhosis mortality in 187 countries between 1980 and 2010 : a systematic analysis. *BMC Med.* 2014;12:1-24
25. Muir AJ. Understanding the Complexities of Cirrhosis. Elsevier HS Journals. 2015;37(8):1822–36.
26. Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. *Lancet.* 2014;6736(14):1–13.
27. Setiati S, Alwi I, Sudoyo AW, Simadibrata K M, Setiyohadi B, Syam FA. Buku Ajar Ilmu Penyakit Dalam. Jakarta : Pusat Penerbitan Departemen Ilmu Penyakit Dalam Fakultas Kedokteran Universitas Indonesia; 2006.
28. Health Data (2017). Indonesia Datasets. Institute for Health Metrics and Evaluation. <http://www.healthdata.org/indonesia> - Diakses Agustus 2019
29. D'Amico G. Natural History and Stages of Cirrhosis. In: Franchis R De, Dell' Era A, editors. *Variceal Hemorrhage.* Milan: Springer US; 2014. p. 22–3.
30. McCormick PA, Jalan R. Hepatic Cirrhosis. In: James S D, Anna S F, editors. *Sherlock's Disease of the Liver and Biliary System.* 13th ed. London: Wiley Blackwell; 2018. p. 107–26.
31. Nayak NC, Jain D. End Stage Chronic Liver Disease – Yesterday, Today and Tomorrow. In: Michelli ML, editor. *Liver Cirrhosis : Causes, Diagnosis and Treatment.* New York: Nova Science Publishers; 2011. p. 59–73.
32. Longo DL, Fauci AS. Harrison Gastroenterologi dan Hepatologi. In: Sandra F, Ayuningtyas P, Iskandar M, editors. Jakarta: Penerbit Buku Kedokteran EGC; 2010. 374–385 p.
33. Li B, Zhang C, Zhan Y. Nonalcoholic Fatty Liver Disease Cirrhosis : A Review of Its Epidemiology , Risk Factors , Clinical Presentation , Diagnosis , Management , and Prognosis. *Can J Gastroenterol Hepatol.* 2018;2018:8. .
34. Radford-smith DE, Powell EE. Haemochromatosis : a clinical update for the practising physician. *Intern Med J.* 2018;28:509–16.
35. Nahon P, Trinchet J, Beaugrand M. Hepatic Iron Overload and Risk of Hepatocellular Carcinoma in Cirrhosis. *Gastroenterol Clin.* 2010;34:1–7.

36. Younossi ZM, Bernstein D, Shiffman ML, Kwo P, Kim WR, Kowdley K V, et al. Diagnosis and Management of Primary Biliary Cholangitis. *Am J Gastroenterol*. 2018;114(1):48–63.
37. Suva M. A Brief Review on Liver Cirrhosis : Epidemiology , Etiology , Pathophysiology , Symptoms , Diagnosis and Its Management. *Inven Rapid Mol Pharmacol*. 2014;2014(2):1–5.
38. Chawla YK, Vijay B. Clinical Clues to the Diagnosis of Cirrhosis. In: Lee SS, Moreau R, editors. *Cirrhosis A Practical Guide to Management*. 1st ed. New Jersey: Wiley Blackwell; 2015. p. 3–10.
39. Inadomi JM, Bhattacharya R, Dornitz JA, Hwang JH. Yamada ' s Handbook of Gastroenterology. 3rd ed. Yamada T, editor. Seattle: Wiley Blackwell; 2013. 432–442 p.
40. Yang YY, Lin HC. Diagnostic Laboratory Test. In: Lee SS, Moreau R, editors. *Cirrhosis A Practical Guide to Management*. 1st ed. New Jersey: Wiley Blackwell; 2015. p.12–20.
41. Rosenberg W, Badrick T, Tanwar S. Liver Disease. In: Rifai N, Horvath AR, Wittwer CT, editors. *TietZ Textbook of Clinical Chemistry and Molecular Diagnostics*. 6th ed. St. Louis: Elsevier; 2018. p. 1348–58.
42. Aubé C, Bazeries P, Lebigot J, Cartier V, Boursier J. Liver fibrosis, cirrhosis, and cirrhosis-related nodules: Imaging diagnosis and surveillance. *Diagn Interv Imaging*. 2017;98(6):455–68.
43. Procopet B, Berzigotti A. Diagnosis of cirrhosis & portal hypertension: Imaging, non-invasive markers of fibrosis & liver biopsy. *Gastroenterol Rep*. 2017;5(2):79–89.
44. Phillip S. Ge, M.D., Bruce A. Runyon MD, C. Treatment of Patients with Cirrhosis. *N Engl J Med*. 2016;375(8):767–77.
45. Pinter M, Trauner M, Peck-radosavljevic M, Sieghart W. Cancer and liver cirrhosis : implications on prognosis and management. *Br Med J*. 2016;1(2):1–10.
46. Kumar A, Kumar A, Riaz SU, Kumar R. Child-Pugh Score Predicts Mortality Better than Model of End Stage Liver Disease : A Study in a Tertiary Care Hospital in the Periphery of Karachi. *Ann Abbasi Shaheed Hosp Karachi Med Dent Coll*. 2018;23(3):130–5.
47. Aulia D, Rahajuningsih D S. Pemeriksaan Penyaring pada Kelainan Hemostasis. In: Rahajuningsih D S, editor. *Hemostasis dan Trombosis*. 6th ed. Jakarta: Balai Penerbit Fakultas Kedokteran Universitas Indonesia; 2018. p. 28–9.
48. Ignjatovic V. Prothrombin Time/International Normalized Ratio. In: Monagle P, editor. *Haemostasis Methods and Protocols*. Melbourne: Springer US; 2013. p. 121–30.
49. Yang R, Moosavi L. Prothrombin time. *Natl Institutes Heal*. 2019;46(12):485–7.
50. Levitt DG, Levitt MD. Human serum albumin homeostasis: A new look at the roles of synthesis, catabolism, renal and gastrointestinal excretion, and the clinical value of serum albumin measurements. *Int J Gen Med*. 2016;9:229–55.
51. Kang JS, Lee MH. Noninvasive Diagnostic and Prognostic Assessment Tools for Liver Fibrosis and Cirrhosis in Patients with Chronic Liver

- Disease. In: Tsoulfas G, editor. Liver Cirrhosis. Rijeka: IntechOpen; 2017. p. 1–49
52. Caraceni P, Domenicali M, Tovoli A, Napoli L, Ricci CS, Tufoni M, et al. European Journal of Internal Medicine Clinical indications for the albumin use : Still a controversial issue. 2013;24:721–8.
  53. Valerio C, Theocharidou E, Davenport A, Agarwal B, Valerio C, Agarwal B, et al. Human albumin solution for patients with cirrhosis and acute on chronic liver failure : Beyond simple volume expansion. 2016;8(7):345–54.
  54. Carolina T, Bashir K. Nephrotic syndrome. Natl Institutes Heal. 2020;21(12):1–6.
  55. Prakash, S., Yadav, K. Microalbuminuria in Diabetes. (2017) Lett Health Biol Sci 2(1): 52- 60.
  56. Tomey MI, Winston JA. Cardiovascular pathophysiology in chronic kidney disease: Opportunities to transition from disease to health. Ann Glob Heal. 2014;80(1):69–76.
  57. Levitt DG, Levitt MD. Protein losing enteropathy: Comprehensive review of the mechanistic association with clinical and subclinical disease states. Clin Exp Gastroenterol. 2017;10:147–68.
  58. Information C, Board SA. Cross-Sectional Guidelines for Therapy with Blood Components and Plasma Derivatives : Chapter 5 Human Albumin – Revised. Transfusion Med Hemotherapy. 2016;43:223–32.
  59. NCBI (2016). Bilirubin. National Center for Biotechnology Information. <https://pubchem.ncbi.nlm.nih.gov/compound/Bilirubin> - Diakses Oktober 2019.
  60. Valaskova P, Muchova L. Metabolism of bilirubin and its biological properties. 2016;24(4):198–202.
  61. Murray RK. Porfirin dan Pigmen Empedu. In: Soeharsono R, Sandra F, Oktavius HO, editors. Biokimia Harper. 29th ed. Jakarta: EGC; 2014. p. 348–52.
  62. Aldemir O. The Genetic Aspect of Thalassemia : From Diagnosis to Treatment. In: Al-Zwaini I, editor. Thalassemia and Other Hemolytic Anemias. London: IntechOpen; 2018. p. 11–25.
  63. Khanderia R, Agravat A. Evaluating the role of indirect bilirubin, urobilinogen and Shine and Lal index as an alternative screening tool for beta thalassemia minor. Int J Res Med Sci. 2015;3(3):730–7
  64. Lovena A, Miro S, Efrida. Karakteristik Pasien Sirosis Hepatis di RSUP Dr. M. Djamil Padang. J Kesehat Andalas. 2017;6(1):5–12.
  65. Patasik YZ, Waleleng BJ, Wantania F. Profil Pasien Sirosis Hati Yang Dirawat Inap Di Rsup Prof. Dr. R. D. Kandou Manado Periode Agustus 2012 – Agustus 2014. e-CliniC. 2015;3(1):3–8.
  66. Hagi M. Perbedaan Rerata Jumlah Trombosit Pada Berbagai Gradasi Sirosis Hepatis Berdasarkan Skor Child Turcotte Pugh di Bagian Penyakit Dalam RSUP. Dr. M.Djamil Padang (skripsi). Universitas Andalas; 2017.
  67. Putri Ratna T. Gambaran Penderita Sirosis Hepatis Berdasarkan Klasifikasi Child Turcotte Pugh dan Penyebab Kematian di RSUP. Dr. M.DJamil Padang (skripsi). Universitas Andalas; 2018.
  68. Shimizu I, Matsumoto T, Suzuki N, Sagara C, Koizumi Y, Asaki T, et al. Chronic liver disease develop more slowly in females than males. Dalam:

- Simizu I, editors. Preventive female sex factors against the development of chronic liver disease. Japan: Bentham eBooks; 2012.p. 3-18
69. Herlida. Hubungan Skor APRI (Aspartat Aminotransferase to Platelet Ratio Index) Dengan Derajat Keparahan Sirosis Hati di RSUD Dokter Soedarso Pontianak (skripsi). Universitas Andalas; 2015.
  70. Yusra Y, Agustino C. Prothrombin time, albumin, and fibrinogen values of the liver cirrhosis stages based on the aspartate aminotransferase-to-platelet ratio index. *J Nat Sci Biol Med.* 2019;10(3):11–5.
  71. Hucke F, Pachta E, Reiberger T, Mandorfer M, Sieghart W, Peck-Radosavljevic M. Prognostic impact of the Baveno IV staging system of portal hypertension in patients with cirrhosis and hepatocellular carcinoma. *J Hepatol.* 2015;62:457
  72. Rajekar H. Complication of Cirrhosis Portal Hypertension: A Review. *J Liver.* 2015;4(4):1–7
  73. Nasirul Islam M, Al Mahtab M, Khan M, Ahmad N, Fazal Karim M. Plasma Prothrombin Time and Esophageal Varices in Patients with Cirrhosis of Liver. *Euroasian J Hepato-Gastroenterology.* 2016;6(1):10–2.
  74. Tripodi A, Primignani M, Mannucci PM, Caldwell SH. Changing Concepts of Cirrhotic Coagulopathy. *Am J Gastroenterol* [Internet]. 2017;112(2):274–81.
  75. Budiayasa DGA, Ariawan Y, Mariadi IK, Wibawa IDN, Purwadi N, Suryadarma IGA. Correlation between Serum Albumin Level and Degree of Esophageal Varices in Patients with Liver Cirrhosis. *Indones J Gastroenterol Hepatol Dig Endosc.* 2011;12(1):23–7
  76. Shah AS, Amrapurkar DN. Natural History of Cirrhosis of Liver after First Decompensation: A Prospective Study in India. *J Clin Exp Hepatol.* 2018;8(1):50–7.
  77. Sungkar I, Dairi LB, Siregar GA. Correlation Between Esophageal Varices and Lok Score as a Non-Invasive Parameter in Liver Cirrhosis Patients. *Indones J Gastroenterol Hepatol Dig Endosc.* 2016;17(2):83–7
  78. Sudha Rani K, Sudarsi B, Siddeswari R, Manohar S. Correlation of Portal Vein Size with Esophageal Varices Severity in Patients with Cirrhosis of Liver with Portal Hypertension. *Int J Sci Res Publ.* 2015;5(1):1–5
  79. Shao L, Han B, An S, Ma J, Guo X, Romeiro FG, et al. Albumin-to-bilirubin score for assessing the in-hospital death in cirrhosis. *Transl Gastroenterol Hepatol.* 2017;2:88.
  80. López-Velázquez JA, Chávez-Tapia NC, Ponciano-Rodríguez G, Sánchez-Valle V, Caldwell SH, Uribe M, et al. Bilirubin alone as a biomarker for short-term mortality in acute-on-chronic liver failure: An important prognostic indicator. *Ann Hepatol.* 2014;13(1):98–104
  81. Tapper EB, Parikh ND, Sengupta N, Mellinger J, Ratz D, Lok ASF, et al. A risk score to predict the development of hepatic encephalopathy in a population-based cohort of patients with cirrhosis. *Hepatology.* 2018;68(4):1498–507.